

PHARMACEUTICAL TURNOVER
Three months ended 30th September 2005

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,235	13	16	651	16	17	388	8	10	196	18	26
<i>Seretide/Advair</i>	737	20	22	417	20	22	246	17	18	74	26	37
<i>Flixotide/Flovent</i>	151	3	7	65	8	10	42	(6)	(2)	44	7	13
<i>Serevent</i>	79	(6)	(4)	25	(17)	(17)	38	(3)	(3)	16	13	23
<i>Flixonase/Flonase</i>	166	12	14	139	16	17	14	(4)	17	13	(5)	(7)
CENTRAL NERVOUS SYSTEM	806	(5)	(3)	517	(6)	(5)	171	(6)	(6)	118	2	7
<i>Seroxat/Paxil</i>	142	(44)	(42)	21	(83)	(82)	49	(19)	(16)	72	-	1
<i>Paxil IR</i>	118	(20)	(18)	1	(98)	(94)	49	(19)	(16)	68	(1)	(1)
<i>Paxil CR</i>	24	(77)	(76)	20	(80)	(80)	-	-	-	4	35	45
<i>Wellbutrin</i>	192	9	11	187	10	11	-	-	-	5	(25)	-
<i>Wellbutrin IR, SR</i>	23	(52)	(49)	19	(54)	(54)	-	-	-	4	(42)	(21)
<i>Wellbutrin XL</i>	169	31	32	168	30	32	-	-	-	1	-	-
<i>Imigran/Imitrex</i>	180	2	3	131	2	3	36	1	-	13	-	8
<i>Lamictal</i>	210	20	22	145	35	37	50	(10)	(7)	15	20	25
<i>Requip</i>	42	41	45	23	62	77	17	22	21	2	24	-
ANTI-VIRALS	664	9	11	333	7	8	194	13	14	137	10	14
HIV	399	5	7	198	(1)	-	154	15	17	47	7	12
<i>Combivir</i>	147	-	2	71	(3)	(3)	58	5	7	18	(1)	6
<i>Trizivir</i>	77	(5)	(3)	43	(8)	(9)	30	-	-	4	4	11
<i>Epivir</i>	65	(13)	(11)	22	(39)	(37)	30	8	11	13	19	18
<i>Ziagen</i>	33	(20)	(21)	13	(34)	(35)	13	(7)	(7)	7	(4)	(13)
<i>Retrovir</i>	12	9	9	5	7	-	4	5	-	3	20	50
<i>Agenerase, Lexiva</i>	31	66	72	20	43	54	10	>100	>100	1	1	8
<i>Epzicom/Kivexa</i>	34	>100	-	24	-	-	9	>100	>100	1	-	-
Herpes	210	16	17	123	23	24	35	8	13	52	6	6
<i>Valtrex</i>	179	20	22	121	24	26	25	10	14	33	10	14
<i>Zovirax</i>	31	(4)	(3)	2	(47)	(33)	10	2	11	19	(1)	(5)
<i>Zeffix</i>	37	9	12	3	11	-	4	(11)	(33)	30	14	25
ANTI-BACTERIALS	349	(2)	-	56	(24)	(21)	157	3	4	136	3	6
<i>Augmentin</i>	149	(6)	(4)	29	(34)	(31)	68	7	8	52	-	2
<i>Augmentin IR</i>	127	(1)	2	9	(38)	(36)	66	6	6	52	1	6
<i>Augmentin ES, XR</i>	22	(29)	(29)	20	(32)	(29)	2	79	100	-	-	-
<i>Zinnat/Ceftin</i>	41	(4)	(2)	2	>100	100	19	(14)	(14)	20	2	5
METABOLIC	396	21	24	268	22	24	49	28	36	79	11	16
<i>Avandia</i>	299	29	33	226	35	38	27	9	13	46	15	24
<i>Avandamet</i>	56	(5)	(5)	39	(24)	(25)	13	>100	>100	4	(8)	-
<i>Boniva</i>	3	-	-	3	-	-	-	-	-	-	-	-
VACCINES	399	20	22	123	82	84	162	7	8	114	-	3
<i>Hepatitis</i>	121	18	20	43	26	26	60	16	18	18	9	13
<i>Infanrix/Pediarix</i>	125	31	32	48	44	45	57	35	39	20	(1)	(5)
ONCOLOGY AND EMESIS	262	5	7	199	8	9	40	(5)	(5)	23	1	5
<i>Zofran</i>	215	6	7	167	8	10	29	(7)	(9)	19	5	12
<i>Hycamtin</i>	26	(2)	-	18	2	6	7	(3)	-	1	(29)	(50)
CARDIOVASCULAR AND UROGENITAL	343	44	48	205	43	44	103	55	63	35	22	30
<i>Coreg</i>	154	39	40	153	40	42	-	-	-	1	(29)	(50)
<i>Levitra</i>	9	(20)	(18)	7	>100	>100	1	(76)	(80)	1	(90)	(67)
<i>Avodart</i>	36	98	>100	20	>100	100	14	75	100	2	>100	>100
<i>Arixtra</i>	7	>100	>100	4	>100	>100	2	>100	100	1	>100	>100
<i>Fraxiparine</i>	49	>100	>100	-	-	-	43	>100	>100	6	>100	>100
<i>Vesicare</i>	4	-	-	4	-	-	-	-	-	-	-	-
OTHER	255	8	11	17	(21)	(19)	76	15	15	162	9	14
<i>Zantac</i>	61	(8)	(8)	15	(16)	(12)	16	(7)	(6)	30	(5)	(6)
	4,709	10	12	2,369	11	12	1,340	9	11	1,000	8	13

Pharmaceutical turnover includes co-promotion income.

PHARMACEUTICAL TURNOVER
Nine months ended 30th September 2005

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	3,647	13	13	1,847	16	14	1,224	8	9	576	14	17
<i>Seretide/Advair</i>	2,152	21	21	1,194	26	24	756	15	16	202	16	22
<i>Flixotide/Flovent</i>	464	2	3	190	3	2	139	(3)	-	135	5	8
<i>Serevent</i>	243	(9)	(8)	75	(25)	(26)	121	(3)	(1)	47	14	18
<i>Flixonase/Flonase</i>	485	12	11	372	10	8	47	(1)	4	66	47	47
CENTRAL NERVOUS SYSTEM	2,333	(11)	(11)	1,466	(14)	(16)	536	(6)	(5)	331	-	2
<i>Seroxat/Paxil</i>	457	(45)	(44)	101	(75)	(75)	147	(26)	(25)	209	(3)	(2)
<i>Paxil IR</i>	366	(31)	(30)	18	(85)	(85)	147	(26)	(25)	201	(4)	(4)
<i>Paxil CR</i>	91	(69)	(69)	83	(71)	(72)	-	-	-	8	37	44
<i>Wellbutrin</i>	522	(10)	(11)	511	(10)	(11)	1	46	54	10	(8)	(9)
<i>Wellbutrin IR, SR</i>	68	(73)	(73)	60	(75)	(75)	1	46	54	7	(27)	(30)
<i>Wellbutrin XL</i>	454	38	36	451	38	36	-	-	-	3	>100	>100
<i>Imigran/Imitrex</i>	509	2	1	366	3	1	106	(2)	(1)	37	(1)	3
<i>Lamictal</i>	621	26	25	405	37	35	175	7	9	41	16	21
<i>Requip</i>	106	26	26	51	35	34	49	18	20	6	18	20
ANTI-VIRALS	1,901	9	8	939	9	7	579	7	8	383	9	11
HIV	1,148	6	6	563	2	-	455	9	10	130	12	14
<i>Combivir</i>	435	3	3	209	1	-	174	3	5	52	6	8
<i>Trizivir</i>	226	(8)	(9)	122	(10)	(12)	93	(5)	(5)	11	(3)	10
<i>Epivir</i>	199	(10)	(10)	71	(33)	(34)	93	8	9	35	18	21
<i>Ziagen</i>	102	(13)	(13)	41	(26)	(27)	43	(4)	(2)	18	9	6
<i>Retrovir</i>	33	4	3	13	1	-	12	(2)	-	8	23	14
<i>Agenerase, Lexiva</i>	79	86	88	50	61	61	25	>100	>100	4	40	33
<i>Epzicom/Kivexa</i>	74	>100	-	57	-	-	15	>100	>100	2	-	-
Herpes	602	13	13	344	23	21	105	-	2	153	3	4
<i>Valtrex</i>	505	20	19	339	25	22	74	9	10	92	12	14
<i>Zovirax</i>	97	(12)	(12)	5	(37)	(38)	31	(17)	(14)	61	(7)	(8)
<i>Zeffix</i>	103	5	7	9	12	13	15	(3)	(6)	79	7	10
ANTI-BACTERIALS	1,114	(4)	(3)	187	(30)	(31)	534	4	6	393	3	4
<i>Augmentin</i>	496	(9)	(8)	104	(39)	(40)	236	5	7	156	7	8
<i>Augmentin IR</i>	410	2	3	28	(28)	(30)	228	3	5	154	8	9
<i>Augmentin ES, XR</i>	86	(38)	(39)	76	(43)	(43)	8	>100	>100	2	(30)	(30)
<i>Zinnat/Ceftin</i>	143	(6)	(4)	6	(11)	(14)	83	(7)	(3)	54	(6)	(4)
METABOLIC	1,108	20	20	750	20	18	134	34	40	224	11	14
<i>Avandia</i>	865	28	28	655	33	31	82	21	24	128	10	15
<i>Avandamet</i>	129	(13)	(13)	88	(32)	(34)	29	>100	>100	12	9	20
<i>Boniva</i>	7	-	-	7	-	-	-	-	-	-	-	-
VACCINES	969	14	15	243	31	29	423	14	16	303	3	4
<i>Hepatitis</i>	331	11	12	102	4	2	170	16	18	59	11	13
<i>Infanrix/Pediarix</i>	310	20	21	108	22	21	148	28	30	54	(1)	-
ONCOLOGY AND EMESIS	745	6	6	554	9	8	125	(4)	(2)	66	2	5
<i>Zofran</i>	608	7	6	460	10	8	94	(5)	(4)	54	4	8
<i>Hycamtin</i>	74	(1)	(1)	49	-	-	21	(3)	-	4	(13)	(20)
CARDIOVASCULAR AND UROGENITAL	965	48	48	549	36	33	310	83	88	106	36	41
<i>Coreg</i>	414	33	31	410	34	32	-	-	-	4	(29)	(33)
<i>Levitra</i>	30	(16)	(19)	26	79	73	3	(77)	(80)	1	(92)	(86)
<i>Avodart</i>	90	>100	>100	44	94	91	40	>100	>100	6	>100	>100
<i>Arixtra</i>	16	>100	>100	9	>100	>100	6	>100	>100	1	>100	>100
<i>Fraxiparine</i>	156	>100	>100	-	-	-	133	>100	>100	23	>100	>100
<i>Vesicare</i>	8	-	-	8	-	-	-	-	-	-	-	-
OTHER	771	4	5	50	(24)	(25)	236	8	9	485	6	7
<i>Zantac</i>	180	(12)	(12)	41	(24)	(24)	47	(17)	(15)	92	(3)	(3)
	13,553	7	7	6,585	6	4	4,101	9	11	2,867	7	10

Pharmaceutical turnover includes co-promotion income.

CONSUMER HEALTHCARE TURNOVER
Three months ended 30th September 2005

	Q3 2005 £m	Growth CER%	£%
Over-the-counter medicines	347	(1)	1
Analgesics	94	10	12
Dermatological	34	(23)	(21)
Gastrointestinal	64	3	8
Respiratory tract	36	(5)	(3)
Smoking control	81	4	7
Natural wellness support	31	(7)	(6)
Oral care	247	4	6
Nutritional healthcare	168	12	14
Total	762	3	6

CONSUMER HEALTHCARE TURNOVER
Nine months ended 30th September 2005

	9 months 2005 £m	Growth CER%	£%
Over-the-counter medicines	1,037	2	3
Analgesics	268	6	7
Dermatological	120	(12)	(11)
Gastrointestinal	182	2	3
Respiratory tract	102	6	6
Smoking control	242	9	9
Natural wellness support	97	(3)	(2)
Oral care	698	2	3
Nutritional healthcare	465	6	6
Total	2,200	3	4

INCOME STATEMENT
Three months ended 30th September 2005

	Q3 2005 £m	Q3 2004 £m	Growth CER%	£%
Turnover:	4,709	4,202	10	12
Pharmaceuticals	762	722	3	6
Consumer Healthcare	5,471	4,924	9	11
TURNOVER	(1,184)	(1,105)	6	7
Cost of sales	4,287	3,819	10	12
Gross profit	(1,884)	(1,648)	13	14
Selling, general and administration	(803)	(696)	15	15
Research and development	183	22		
Other operating income				
Operating profit:	1,553	1,319	12	18
Pharmaceuticals	230	178	28	29
Consumer Healthcare	1,783	1,497	14	19
OPERATING PROFIT	67	48		
Finance income	(113)	(108)		
Finance expense	16	14		
Share of after tax profits of associates and joint ventures				
PROFIT BEFORE TAXATION	1,753	1,451	16	21
Taxation	(500)	(404)		
<i>Tax rate %</i>	28.5%	27.8%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,253	1,047	15	20
Profit attributable to minority interests	46	39		
Profit attributable to shareholders	1,207	1,008		
EARNINGS PER SHARE	21.3p	17.7p	16	20
Diluted earnings per share	21.1p	17.6p		

INCOME STATEMENT
Nine months ended 30th September 2005

	9 months 2005 £m	9 months 2004 £m	Growth CER%	£%
Turnover:				
Pharmaceuticals	13,553	12,625	7	7
Consumer Healthcare	2,200	2,125	3	4
	15,753	14,750	7	7
TURNOVER				
	(3,466)	(3,184)	8	9
Cost of sales				
	12,287	11,566	6	6
Gross profit				
	(5,210)	(5,156)	1	1
Selling, general and administration	(2,168)	(2,051)	6	6
Research and development	332	156		
Other operating income				
	4,719	4,094	15	15
Operating profit:				
Pharmaceuticals	522	421	23	24
Consumer Healthcare				
	5,241	4,515	15	16
OPERATING PROFIT				
	172	145		
Finance income	(326)	(292)		
Finance expense	39	44		
Share of after tax profits of associates and joint ventures	-	45		
	5,126	4,457	14	15
PROFIT BEFORE TAXATION				
Taxation	(1,461)	(1,236)		
<i>Tax rate %</i>	28.5%	27.7%		
	3,665	3,221	13	14
PROFIT AFTER TAXATION FOR THE PERIOD				
	98	87		
Profit attributable to minority interests	3,567	3,134		
Profit attributable to shareholders				
	62.8p	54.6p	14	15
EARNINGS PER SHARE				
	62.3p	54.4p		
Diluted earnings per share				